Brought to you by 
Ribozyme, Elan in JV to develop treatment for breast cancer
15 Apr 2003
Executive Summary
Ribozyme (develops ribozyme therapeutics) and Elan Pharmaceutical Technologies have formed a joint venture to research, develop, and possibly market Ribozyme's Herzyme against human epidermal growth factor receptor type 2 (HER-2) for the treatment of breast and other cancers.
Deal Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Liposomes
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ribozyme, Elan in JV to develop treatment for breast cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice